Abstract
Introduction: Coronaviruses (COVID-19) is an emerging virus with severe respiratory infection. Despite several efforts, so far there is no medicine to fight it and use it as the ideal treatment. OBJECTIVES: This study aims to describe the role of hydroxychloroquine in the treatment of patients with COVID-19 and thus present its benefits in the respective doses.
 Methodology: The methodology used was the systematic review with meta-analysis.
 Results: From the reading of the 75 papers found, only three articles were excluded for not presenting a complete abstract, 65 were excluded for not presenting eligibility according to the inclusion criteria, 01 was excluded for reaching a methodological score below 20 points in Down and Black (1998) and ending the process of inclusion of the articles, only 06 articles were included and included 894 patients.
 Conclusion: Despite the small number of published articles, this meta-analysis found that the use of hydroxychloroquine as an adjunct therapy in the follow-up of COVID-19 in patients with mild to severe clinical signs brings benefits and avoids hospitalization in intensive care.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Asian Journal of Research in Medical and Pharmaceutical Sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
